Company: TELO
Filing Date: 2025-11-10
Form Type: 10-Q
Source: 0001493152-25-021496
Chunk: 12

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-11-10
Form: 10-Q
Item: Item 1
Chunk 12
---
On
May 19, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an agreement to raise $3 million in equity financing
through a direct investment by The Bayshore Trust, an entity affiliated with the Company’s largest shareholder. The transaction
was structured as a straight restricted common stock deal with no warrants. The Company issued 333,334 restricted shares of its common
stock, no par value (the “Common Stock”) at a purchase price of $3.00 per share, representing an 18% premium to the closing
share price of the Common Stock of $2.54 on the date of execution (the “Bayshore Financing”). The Company received the initial
payment of $1 million for the Bayshore Financing on May 20, 2025. In July 2025, an additional $2 million was received, for the issuance
of 666,666 shares.

License
agreement - See Note 3.

Note
5. Stockholders’ equity (deficit):

Capital
stock

The
Company has the authority to issue 400,000,000 shares of capital stock, consisting of 300,000,000 shares of Common Stock and 100,000,000
shares of undesignated preferred stock, whose rights and privileges will be defined by the Board of Directors when a series of preferred
stock is designated.

Investment
from Largest Shareholder

On
May 19, 2025, Telomir Pharmaceuticals, Inc. (the “Company”) entered into an agreement to raise $3 million in equity financing
through a direct investment by The Bayshore Trust, an entity affiliated with the Company’s largest shareholder. The transaction
was structured as a straight restricted common stock deal with no warrants. The Company issued 333,334 restricted shares of its common
stock, no par value (the “Common Stock”) at a purchase price of $3.00 per share, representing an 18% premium to the closing
share price of the Common Stock of $2.54 on the date of execution (the “Bayshore Financing”). The Company received the initial
payment of $1 million for the Bayshore Financing on May 20, 2025. In July 2025, an additional $2 million was received, for the issuance
of 666,667 shares.

ATM
Agreement

On
February 14, 2025, the Company filed a shelf registration statement with the SEC to facilitate the